ReviewOpen Access
Revisiting potential druggable targets against <scp>SARS‐CoV</scp>‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
Author Affiliations
Bangladesh Agricultural University, Dongguk University, East West University, Shahjalal University of Science and Technology, ...
Published InDrug Development Research
Year2020
Citations44
Abstract
Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID-19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines, which may require considerable time. In this uncertainty, repurposing the existing antiviral drugs could be the best strategy to speed up the discovery of effective therapeutics against SARS-CoV-2. Moreover, drug repurposing may leave some vital information on druggable targets that could be capitalized in target-based drug discovery. Information on…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.